Examining blood markers after treatment for severe strokes
Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion: a Prospective, Registry Study
This study is testing if certain blood markers can help doctors understand how well patients with severe strokes are doing after they receive a specific treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | General Hospital of Shenyang Military Region Academic / other |
| Locations | 1 site (Shenyang) |
| Trial ID | NCT06383182 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with acute ischemic stroke caused by large vessel occlusion who are undergoing endovascular treatment. It aims to identify serum biomarkers that may correlate with clinical outcomes following the procedure. By analyzing these biomarkers, researchers hope to better understand the factors contributing to poor prognoses in these patients. The study includes adults aged 18-80 who meet specific clinical criteria and excludes those with certain medical conditions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 with acute anterior circulation large vessel occlusion who are scheduled for endovascular treatment.
Not a fit: Patients with contraindications to treatment, severe comorbidities, or those who have had a hemorrhagic stroke will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of patients at risk for poor outcomes after stroke treatment.
How similar studies have performed: Other studies have explored biomarkers in stroke patients, but this specific approach focusing on large vessel occlusion and endovascular treatment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age: 18-80 years; 2. Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment; 3. Pre-stroke mRS: 0-1; 4. Baseline NIHSS: ≥6; 5. Signed informed consent. Exclusion Criteria: 1. The presence of contraindications to internal jugular vein cannulation; 2. Receiving intravenous thrombolysis; 3. Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage); 4. Coagulation disorders, systemic bleeding tendency, thrombocytopenia (\<100×109/L); 5. Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases; 6. Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg); 7. Pregnant or lactating women; 8. Other conditions who are not suitable for this trial by investigator.
Where this trial is running
Shenyang
- General Hospital of Northern Theater Command — Shenyang, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.